Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

I am proposing that all companies currently engaged in developing biosimilars join hands with their regulatory and scientific ...

Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

As global markets navigate the uncertainties surrounding the incoming Trump administration and fluctuating economic indicators, small-cap stocks have experienced varied performance, with indices like ...